Avidity Biosciences Profit Margin

Avidity Biosciences (RNA) currently reports a profit margin of -1590.27% as of March 2026. That compares with -4136.0% in the prior-year period — up 61.6% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Avidity Biosciences's profit margin history and peer comparisons.

Avidity Biosciences's profit margin increased from -4136.0% to -1590.27% — a 61.6% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Avidity Biosciences's profit margin of -1590.27% is lower than the Healthcare sector average of 15.29%. That is roughly 10498.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Avidity Biosciences's current -1590.27% should be judged against Healthcare norms (sector average: 15.29%) and against RNA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -1590.27%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Avidity Biosciences, and consider following RNA for alerts when major investors trade the stock.